中文
Earlier issues
Announcement
More
Progress in Chemistry 2013, Vol. 25 Issue (09): 1429-1449 DOI: 10.7536/PC130747 Previous Articles   Next Articles

Special Issue: 酶化学

Phase 3 Trials in Breast Cancer Prevention：Focus on Estrogen-Targeting Agents, Selective Estrogen Receptor Modulators and Aromatase Inhibitors

Barbara K. Dunn*   

  1. Medical Officer, National Cancer Institute, Division of Cancer Prevention
  • Received: Online: Published:
  • Contact: Barbara K. Dunn E-mail:dunnb@mail.nih.gov
Richhtml ( 1 ) PDF ( 739 ) Cited
Export

EndNote

Ris

BibTeX

Worldwide, breast cancer is the most common cancer in women, with 1.38 million breast cancer diagnoses cases estimated for 2008, accounting for 23% of all cancers in women. Breast cancer has the highest mortality rate of all cancers among women worldwide. Although technological advances in early detection and treatment have made inroads into these rates, breast cancer associated mortality remains high. Hence, interest has emerged in exploring approaches to preventing this disease and developing risk models to identify women most likely to benefit from preventive interventions. The current chapter addresses breast cancer risk-reducing agents that have progressed in their development to testing in phase Ⅲ clinical trials or in some cases to formal approval for a breast cancer risk reduction indication. The discussion here concentrates on agents targeting estrogen receptor (ER)-positive breast cancers, specifically selective ER modulators (SERMs) and aromatase inhibitors (AIs). The large phase III clinical trials assessing efficacy of these agents in breast cancer prevention are the focus, as these represent the gold standard in clinical testing and serve as the basis for approval of these anti-estrogens for risk reduction of breast cancer among high-risk women.

Key words: breast cancer prevention, selective estrogen receptor modulators, aromatase inhibitors, phase Ⅲ clinical trials, risk models

CLC Number: 

[1] Ferlay J, Shin H R, Bray F, Forman D, Mathers C, Parkin D M. Int. J. Cancer., 2010, 127: 2893—2917
[2] Cancer Research U K. Cancer Stats.Breast Cancer 2011.[2013-03-18]. http://www.cancerresearchuk.org/cancer-info/cancerstats/world/breast-cancer-world/#Mortality
[3] Siegel R, Naishadham D, Jemal A. CA Cancer J. Clin., 2013, 63:11—30
[4] Nelson H D, Huffman L H, Fu R, Harris E L. Ann. Intern. Med., 2005, 143: 362—379
[5] Kurian A W, Gong G D, Chun N M, Mills M A, Staton A D, Kingham K E, Crawford B B, Lee R, Chan S, Donlon S S, Ridge Y, Panabaker K, West D W, Whittemore A S, Ford J M. J. Clin. Oncol., 2008, 26: 4752—4758
[6] Howell A, Astley S, Warwick J, Stavrinos P, Sahin S, Ingham S, McBurney H, Eckersley B, Harvie M, Wilson M, Beetles U, Warren R, Hufton A, Sergeant J, Newman W, Buchan I, Cuzick J, Evans D G. J. Intern. Med., 2012, 271: 321—330
[7] Boughey J C, Hartmann L C, Anderson S S, Degnim A C, Vierkant R A, Reynolds C A, Frost M H, Pankratz V S. J. Clin. Oncol., 2010, 28: 3591—3596
[8] Baker L H. CA Cancer J. Clin., 1982, 32: 194—225
[9] Gail M H, Brinton L A, Byar D P, Corle D K, Green S B, Schairer C, Mulvihill J J. J. Natl. Cancer Inst., 1989, 81: 1879—1886
[10] Costantino J P, Gail M H, Pee D, Anderson S, Redmond C K, Benichou J, Wieand H S. J. Natl. Cancer Inst., 1999, 91: 1541—1548
[11] NCI Breast Cancer Risk Assessment Tool. 2011, (2012-05-16).[2013-03-19]. http://www.cancer.gov/bcrisktool/
[12] Gail M H. J. Natl. Cancer Inst., 2008, 100: 1037—1041
[13] Wacholder S, Hartge P, Prentice R, Garcia-Closas M, Feigelson H S, Diver W R, Thun M J, Cox D G, Hankinson S E, Kraft P, Rosner B, Berg C D, Brinton L A, Lissowska J, Sherman M E, Chlebowski R, Kooperberg C, Jackson R D, Buckman D W, Hui P, Pfeiffer R, Jacobs K B, Thomas G D, Hoover R N, Gail M H, Chanock S J, Hunter D J. N. Engl. J. Med., 2010, 362: 986—993
[14] Arun B, Dunn B K, Ford L G, Ryan A. Semin. Oncol., 2010, 37: 367—383
[15] Jordan V C, Ed. Tamoxifen. A Guide for Clinicians and Patients. Huntington, NY: PRR, Inc., 1996
[16] Nayfield S G, Karp J E, Ford L G, Dorr F A, Kramer B S. J. Natl. Cancer Inst., 1991, 83: 1450—1459
[17] Early Breast Cancer Trialists' Collaborative Group. Lancet, 1998, 351: 1451—1467.
[18] Early Breast Cancer Trialists' Collaborative Group. Lancet, 2005, 365: 1687—1717
[19] Fisher B, Costantino J, Redmond C, et al. N. Engl. J. Med., 1989, 320: 479—484
[20] Fisher B, Costantino J P, Wickerham D L, et al. J. Natl. Cancer Inst., 1998, 90: 1371—1388
[21] Fisher B, Costantino J P, Wickerham D L, et al. J. Natl. Cancer Inst., 2005, 97: 1652—1662
[22] Powles T, Eeles R, Ashley S, et al. Lancet, 1998, 352: 98—101
[23] Powles T J, Ashley S, Tidy A, Smith I E, Dowsett M. J. Natl. Cancer Inst., 2007, 99: 283—290
[24] Veronesi U, Maisonneuve P, Costa A, et al. Lancet, 1998, 352: 93—97
[25] Veronesi U, Maisonneuve P, Rotmensz N, et al. J. Natl. Cancer Inst., 2003, 95: 160—165
[26] Cuzick J, Forbes J, Edwards R, et al. Lancet, 2002, 360: 817—824
[27] Cuzick J. Eur. J. Cancer, 1998, 34: 1647—1648
[28] Cuzick J, Forbes J F, Sestak I, et al. J. Natl. Cancer Inst., 2007, 99: 272—282
[29] Cuzick J, Powles T, Veronesi U, et al. Lancet, 2003, 361: 296—300
[30] Ettinger B, Black D M, Mitlak B H, et al. JAMA, 1999, 282: 637—645
[31] Cummings S R, Eckert S, Krueger K A, et al. JAMA, 1999, 281: 2189—2197
[32] Vogel V G, Costantino J P, Wickerham D L, et al. JAMA, 2006, 295: 2727—2741
[33] Vogel V G, Costantino J P, Wickerham D L, et al. Cancer Prev. Res. (Phila), 2010, 3: 696—706
[34] Cuzick J. Cancer Prev. Res. (Phila), 2010, 3: 689—691
[35] Cummings S R, Ensrud K, Delmas P D, LaCroix A Z, Vukicevic S, Reid D M, Goldstein S, Sriram U, Lee A, Thompson J, Armstrong R A, Thompson D D, Powles T, Zanchetta J, Kendler D, Neven P, Eastell R. PEARL Study Investigators. N. Engl. J. Med., 2010, 362: 686—696
[36] LaCroix A Z, Powles T, Osborne C K, Wolter K, Thompson J R, Thompson D D, Allred D C, Armstrong R, Cummings S R, Eastell R, Ensrud K E, Goss P, Lee A,Neven P, Reid D M, Curto M, Vukicevic S. PEARL Investigators. J. Natl. Cancer Inst., 2010, 102: 1706—1715
[37] Cummings S R, McClung M, Reginster J Y, Cox D, Mitlak B, Stock J, Amewou-Atisso M, Powles T, Miller P, Zanchetta J, Christiansen C. J. Bone Miner. Res., 2011, 26: 397—404
[38] Coombes R C, Hall E, Gibson L J, Paridaens R, Jassem J, Delozier T, Jones S E, Alvarez I, Bertelli G, Ortmann O, Coates A S, Bajetta E, Dodwell D, Coleman R E, Fallowfield L J, Mickiewicz E, Andersen J, Lønning P E, Cocconi G, Stewart A, Stuart N, Snowdon C F, Carpentieri M, Massimini G, Bliss J M, vande Velde C. Intergroup Exemestane Study. N. Engl. J. Med., 2004, 350: 1081—1092
[39] Coombes RC, Kilburn LS, Snowdon CF, et al. Lancet, 2007, 369:559—570
[40] Richardson H, Johnston D, Pater J, Goss P. Curr. Oncol., 2007, 14: 89—96
[41] Khuder S A, Mutgi A B. Br. J. Cancer, 2001, 84: 1188—1192
[42] Hwang D, Scollard D, Byrne J, Levine E. J. Natl. Cancer Inst., 1998, 90: 455—460
[43] Bresalier R S, Sandler R S, Quan H, et al. N. Engl. J. Med., 2005, 352: 1092—1102
[44] Solomon S D, McMurray J J, Pfeffer M A, et al. N. Engl. J. Med., 2005, 352: 1071—1080
[45] Goss P E, Ingle J N, Ales-Martinez J E, et al. N. Engl. J. Med., 2011, 364: 2381—2391
[46] Decensi A, Dunn B K, Puntoni M, Gennari A, Ford L G. Cancer Discovery, 2012, 2: 25—40
[47] Baum M, Budzar A U, Cuzick J, Forbes J, Houghton J H, Klijn J G, Sahmoud T. ATAC Trialists' Group. Lancet, 2002, 359: 2131—2139
[48] Baum M, Buzdar A, Cuzick J, et al. Cancer, 2003, 98: 1802—1810
[49] Howell A, Cuzick J, Baum M, et al. Lancet, 2005, 365: 60—62
[50] Forbes J F, Cuzick J, Buzdar A, Howell A, Tobias J S, Baum M. Lancet Oncol., 2008, 9: 45—53
[51] Cuzick J, Sestak I, Baum M, et al. Lancet Oncol., 2010, 11: 1135—1141
[52] Sestak I, Cuzick J, Sapunar F, et al. Lancet Oncol., 2008, 9: 866—872
[53] Cuzick J. Recent Results Cancer Res., 2003, 163: 96—103; discussion 264—266
[54] Cuzick J. J. Clin. Oncol., 2005, 23: 1636—1643
[55] Cuzick J. Expert Rev. Anticancer Ther., 2008, 8: 1377—1385
[56] International Breast Cancer Intervention Study II. 2012,[2013-03-21]. http://www.ibis-trials.org/
[57] International Breast Cancer Intervention Study-II. Accrual numbers., 2012. [2013-04-03]. http://www.ibis-trials.org/news/viewStory.php?storyId=186
[58] Davies C, Pan H, Godwin J, et al. Lancet, 2013, 381(9869): 805—816
[59] Lazzeroni M, Serrano D, Dunn BK, et al. Breast Cancer Res., 2012,14:214
[60] Heckman-Stoddard B M, Lee O, Lazzeroni M, Khan S, DeCensi A, Dunn B K. Innovative Approaches to Tamoxifen Administration for Breast Cancer Prevention. In: Tamoxifen Concepts and Cancer: New Paradigms: Nova ScienceHauppauge. (Mello RAd, Ed.), NY: Publishers, 2013. in press.
[61] Decensi A, Bonanni B, Guerrieri-Gonzaga A, et al. J. Natl. Cancer Inst., 1998, 90: 1461—1467
[62] Decensi A, Gandini S, Guerrieri-Gonzaga A, et al. J. Clin. Oncol., 1999, 17: 2633—2638
[63] Decensi A, Robertson C, Viale G, et al. J. Natl. Cancer Inst., 2003, 95: 779—790
[64] Kisanga E R, Gjerde J, Guerrieri-Gonzaga A, et al. Clin. Cancer Res., 2004, 10: 2336—2343
[65] Decensi A, Robertson C, Guerrieri-Gonzaga A, et al. J. Clin. Oncol., 2009, 27: 3749—3756
[66] Waters E A, Cronin K A, Graubard B I, Han P K, Freedman A N. Cancer Epidemiol Biomarkers Prev., 2010, 19: 443—446
[67] Tchou J, Hou N, Rademaker A, Jordan V C, Morrow M. Cancer, 2004, 100: 1800—1806
[68] Decensi A, Puntoni M, Goodwin P, et al. Cancer Prev. Res. (Phila), 2010, 3: 1451—1461
[69] Bonanni B, Puntoni M, Cazzaniga M, et al. J. Clin. Oncol., 2012, 30(21): 2593—2600
[70] Szabo E. Semin. Oncol., 2010, 37: 359—366
[71] Goss P E, Ingle J N, Martino S, et al. N. Engl. J. Med., 2003, 349: 1793—1802
[72] Thurlimann B, Keshaviah A, Coates AS, et al. N. Engl. J. Med., 2005, 353: 2747—2757
[73] Coates A S, Keshaviah A, Thurlimann B, et al. J. Clin. Oncol., 2007, 25: 486—492
[74] Regan M M, Neven P, Giobbie-Hurder A, et al. Lancet Oncol., 2011, 12: 1101—1108
[75] Veronesi U, Maisonneuve P, Rotmensz N, et al. J. Natl. Cancer Inst., 2007, 99: 727—737otmensz N, et al. J. Natl. Cancer Inst., 2007, 99:727-737
[1] Michael B. Sporn, Karen T. Liby. A Mini-Review of Chemoprevention of Cancer——Past, Present, and Future [J]. Progress in Chemistry, 2013, 25(09): 1421-1428.